Jan 12, 2024, 08:03 by

OneMedNet Corporation announced a partnership with Beacon Health System, Inc. to promote new patient care diagnostic and treatment solutions using OneMedNet’s iRWD™. Life Science organizations of all types are taking advantage of existing real world data within several product development stages including conceptualization, development, validation, regulatory approval, and post-market surveillance. The OneMedNet iRWD network consists of over 235 healthcare systems and providers who are well-recognized for their exceptional patient care.

Jan 11, 2024, 08:59 by

Blue Spark Technologies, Inc., a proven innovative digital health technology (DHT) leader in enabling AI-powered remote patient monitoring (RPM) to support precision patient-centric drug development, proudly announces the appointment of Dr. MaryAnne Rizk, a recognized leader in drug development technological innovation, to the Company’s advisory board.

Jan 10, 2024, 01:00 by User Not Found

Clinical Research News | The “power of the team approach” was on full display for a study designed to understand the contribution of asymptomatic carriers to the spread of Clostridioides difficile in hospitals.

Jan 9, 2024, 06:24 by

I wanted to reach out with the latest news from Verdot, who have recently forged a strategic partnership with Bio-Link, a prominent Chinese bioprocessing company. The collaboration aims to advance biopharmaceutical manufacturing in China, with Bio-Link becoming the major distributor for Verdot’s innovative chromatography columns in the Chinese market The full release and images are below. Thank you Charlotte

Jan 9, 2024, 01:00 by User Not Found

Clinical Research News | The “power of the team approach” was on full display for a study designed to understand the contribution of asymptomatic carriers to the spread of Clostridioides difficile in hospitals.

Jan 8, 2024, 08:12 by

Jan 8, 2024, 08:12 by

Jan 5, 2024, 09:55 by

— Results Demonstrated that LYBALVI was Generally Well Tolerated With Stability of Body Weight and Metabolic Profile, and Durable Symptom Control, for Up to Four Years of Treatment —

Jan 5, 2024, 09:55 by

John Potthoff Transitions to Chairman, Barry Simms Promoted to CEO

Jan 5, 2024, 01:00 by User Not Found

Clinical Research News | Cell and gene therapies (CGT) have made substantial progress in recent years thanks to several breakthroughs and higher flow of funds into the space. Despite this progress, the challenges of working with living therapies remain highly complex, risk-laden, and time-consuming.

Jan 4, 2024, 01:00 by User Not Found

Clinical Research News | Last year was full of growing pains for clinical research as decentralized trial models continued to mature, AI took a more aggressive role in study planning and execution, and the player landscape continued to shake out. Here are the top stories from Clinical Research News as well as thought leaders in the industry

Jan 3, 2024, 08:51 by

Mundipharma announces European approval of REZZAYO® (rezafungin) for the treatment of Invasive Candidiasis in adults. Approval based on positive results from the pivotal ReSTORE Phase III clinical trial and supported by the STRIVE Phase II clinical trials and extensive nonclinical development program.1,2 Rezafungin represents the first new treatment option in over 15 years for patients with invasive candidiasis.3

Jan 3, 2024, 01:00 by User Not Found

Clinical Research News | We spoke with leaders and experts in the Clinical Research community about their predictions for 2024.

Jan 2, 2024, 09:24 by

Jan 2, 2024, 09:24 by

Jan 2, 2024, 09:24 by

BOC Sciences, a leading chemical supplier, has partnered with Spaya, an AI-powered chemical synthesis platform, to enhance the portfolio of commercially available materials by listing an unprecedented 140,000+ chemical products.

Jan 2, 2024, 09:24 by

Jan 2, 2024, 09:24 by

Jan 2, 2024, 09:24 by

Jan 2, 2024, 09:24 by

Columbus, OH, December 18, 2023 - Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), announced that it has been selected by Ultragenyx (NASDAQ: RARE) to perform late-stage Process Performance Qualification (PPQ) manufacturing of the company’s UX111 gene therapy for the potential treatment of Sanfilippo Syndrome (MPS IIIA).